## Supporting information

## Two novel Pd thiosemicarbazone complexes as efficient and selective antitumoral drugs

## Tania Hidalgo, ${ }^{\text {a }}$ David Fabra, ${ }^{\mathrm{b}}$ Raul Allende, ${ }^{\text {b }}$ Ana I Matesanz, ${ }^{\text {b }}$ Patricia Horcajada, ${ }^{* a}$ Tarita Biver, ${ }^{* \mathrm{c}}$ Adoracion

```
G.Quiroga.*b
```


## Table of contents

Figure S1. 2D $\left[{ }^{1} \mathrm{H},{ }^{13} \mathrm{C}\right]$ HMBC NMR spectra for complex $\left[\operatorname{Pd}(\mathrm{L})_{2}\right]$ .....  2
Figure S2. Aliphatic area of the 2D $\left[{ }^{1} \mathrm{H},{ }^{13} \mathrm{C}\right] \mathrm{HMBC}$ NMR spectra of complex [PdLCl(DMSO)] .....  2
Figure S3. Aromatic area of the spectra (A) HMQC and (B) HMBC for complex [PdLCl(DMSO)] .....  3
Table S1. Selected bond distances ( A ) and angles $\left({ }^{\circ}\right)$ for complex [PdLCI(DMSO)]. .....  3
Figure S4. (A) UV-Vis spectra of the complexes $\left[\mathrm{Pd}(\mathrm{L})_{2}\right]\left(2.50 \times 10^{-3} \mathrm{M}, 3 \% \mathrm{DMSO}\right)$ and $[\mathrm{PdLCl}(\mathrm{DMSO})]$ ( $2.50 \times 10^{-3} \mathrm{M}, 5 \% \mathrm{DMSO}$ ) in Tris HCl solution, recorded at different times. (B) UV-Vis spectra of the complexes $\left[\mathrm{Pd}(\mathrm{L})_{2}\right]\left(2.50 \times 10^{-3} \mathrm{M}, 3 \% \mathrm{DMSO}\right)$ and $[\mathrm{PdLCl}(\mathrm{DMSO})]\left(2.50 \times 10^{-3} \mathrm{M}, 5 \% \mathrm{DMSO}\right)$ in Tris-HCl solution with $4 \mu \mathrm{M}$ of NaCl , recorded at different times. .....  4
Figure S5. Spectroscopic characterization of $\left[\mathrm{Pd}(\mathrm{L})_{2}\right]$ and $[\mathrm{PdLCl}(\mathrm{DMSO})]$ complexes in Tris-HCl 5 mM , $\mathrm{NaCl} 100 \mathrm{mM}, \mathrm{pH} 7.4$ at $25{ }^{\circ} \mathrm{C}$ .....  4
Figure S6. (A), (C) Stability of $\left[\mathrm{Pd}(\mathrm{L})_{2}\right]$ as a function of the temperature (from 25 to $95{ }^{\circ} \mathrm{C}$ ) and (B), (D) Stability of [PdLCI(DMSO)] with temperature .....  5
Table S2. $\mathrm{IC}_{50}$ and selective index values of $\left[\mathrm{Pd}(\mathrm{L})_{2}\right],[\mathrm{PdLCl}(\mathrm{DMSO})]$ and cisplatin after 72 h of incubation with HL-60, Caco-2 and PC-3 cells .....  .5
Table S3. Effect of $\left[\operatorname{Pd}(\mathrm{L})_{2}\right]$ and $[\mathrm{PdLCl}(\mathrm{DMSO})]$ complexes in the cell cycle distribution of Caco-2 and PC-3 cell line after 72h of treatment .....  6
Figure S7. Subcellular distribution of $\left[\mathrm{Pd}(\mathrm{L})_{2}\right],[\mathrm{PdLCl}(\mathrm{DMSO})]$ and their respective precursors in A$)$ Caco-2 and B) PC-3 cells after 72 h of incubation with $5 \mu \mathrm{M}$ of each complex .....  6
Figure S8. Spectrophotometric titrations of the complexes with biosubstrates .....  7
Table S4. DNA/BSA binding constants $\left(K_{\mathrm{b}}\right)$ values for different $\operatorname{Pd}(I I)$-thiosemicarbazone complexes. DNA is always natural DNA from calf thymus ..... 8
Figure S9. Binding isotherms of fluorescence exchange reaction of $(A) E t B r$-saturated DNA with$\left[\mathrm{Pd}(\mathrm{L})_{2}\right]$ and $[\mathrm{PdLCl}(\mathrm{DMSO})]$ and (B) Et-Br-saturated RNA (poly(rA)•poly(rU)) with $\left[\mathrm{Pd}(\mathrm{L})_{2}\right]$ and[PdLCl(DMSO)] 9
Table S5. Crystal data and structure refinement results for compound [PdLCl(DMSO)]. ..... 10


Figure S1. 2D $\left[{ }^{1} \mathrm{H},{ }^{13} \mathrm{C}\right]$ HMBC NMR spectra for complex $\left[\operatorname{Pd}(\mathrm{L})_{2}\right]$.


Figure S2. Aliphatic area of the $2 \mathrm{D}\left[{ }^{1} \mathrm{H},{ }^{13} \mathrm{C}\right]$ HMBC NMR spectra of complex [PdLCI(DMSO)]. The new DMSO methyl group signal is indicated with an asterisk (*).


Figure S3. Aromatic area of the spectra (A) HMQC and (B) HMBC for complex [PdLCI(DMSO)].

Table S1. Selected bond distances ( A ) and angles ( ${ }^{\circ}$ ) for complex [PdLCI(DMSO)].

| Bond lengths (Å) |  | Angles ( ${ }^{\circ}$ ) |  |
| :---: | :---: | :---: | :---: |
| $\mathrm{C}_{1}-\mathrm{N}_{2}$ | $1.288(9)$ | $\mathrm{N}_{1}-\mathrm{Pd}_{1}-\mathrm{S}_{1}$ | $83.37(19)$ |
| $\mathrm{C}_{1}-\mathrm{N}_{3}$ | $1.388(10)$ | $\mathrm{N}_{1}-\mathrm{Pd}_{1}-\mathrm{S}_{2}$ | $171.77(19)$ |
| $\mathrm{C}_{1}-\mathrm{S}_{1}$ | $1.752(7)$ | $\mathrm{N}_{1}-\mathrm{Pd}_{1}-\mathrm{Cl}_{1}$ | $96.67(19)$ |
| $\mathrm{C}_{8}-\mathrm{N}_{1}$ | $1.297(9)$ | $\mathrm{S}_{1}-\mathrm{Pd}_{1}-\mathrm{Cl}_{1}$ | $177.03(9)$ |
| $\mathrm{N}_{1}-\mathrm{N}_{2}$ | $1.388(9)$ | $\mathrm{S}_{2}-\mathrm{Pd}_{1}-\mathrm{Cl}_{1}$ | $89.71(8)$ |
| $\mathrm{Pd}_{1}-\mathrm{Cl}_{1}$ | $2.350(2)$ | ${ }^{*} \mathrm{~S}_{1}-\mathrm{Pd}_{1}-\mathrm{S}_{2}$ | $90.53(8)$ |
| $\mathrm{Pd}_{1}-\mathrm{N}_{1}$ | $2.075(6)$ | $\mathrm{N}_{6}-\mathrm{Pd}_{2}-\mathrm{S}_{3}$ | $84.15(19)$ |
| $\mathrm{Pd}_{1}-\mathrm{S}_{1}$ | $2.234(2)$ | $\mathrm{N}_{6}-\mathrm{Pd}_{2}-\mathrm{S}_{4}$ | $173.28(18)$ |
| $\mathrm{Pd}_{1}-\mathrm{S}_{2}$ | $2.249(2)$ | $\mathrm{N}_{6}-\mathrm{Pd}_{2}-\mathrm{Cl}_{2}$ | $96.29(19)$ |
|  |  | $\mathrm{S}_{3}-\mathrm{Pd}_{2}-\mathrm{Cl}_{2}$ | $179.12(10)$ |
|  | $\mathrm{S}_{4}-\mathrm{Pd}_{2}-\mathrm{Cl}_{2}$ | $89.61(8)$ |  |
|  |  | $\mathrm{S}_{3}-\mathrm{Pd}_{2}-\mathrm{S}_{4}$ | $89.99(7)$ |
|  |  |  |  |

*As it can be found in the CIF file, the structure shows the presence of two symmetry-independent molecules which do not differ significantly from each other


Figure S4. (A) UV-Vis spectra of the complexes $\left[\mathrm{Pd}(\mathrm{L})_{2}\right]\left(2.50 \times 10^{-5} \mathrm{M}, 3 \% \mathrm{DMSO}\right)$ and $[\mathrm{PdLCl}(\mathrm{DMSO})]\left(2.50 \times 10^{-5}\right.$ $\mathrm{M}, 5 \% \mathrm{DMSO}$ ) in Tris HCl solution, recorded at different times. (B) UV-Vis spectra of the complexes $\left[\mathrm{Pd}(\mathrm{L})_{2}\right]$ $\left(2.50 \times 10^{-5} \mathrm{M}, 3 \% \mathrm{DMSO}\right)$ and [PdLCl(DMSO)] $\left(2.50 \times 10^{-5} \mathrm{M}, 5 \% \mathrm{DMSO}\right)$ in Tris- HCl solution with $4 \mu \mathrm{M}$ of NaCl , recorded at different times.


Figure S5. Spectroscopic characterization of $\left[\mathrm{Pd}(\mathrm{L})_{2}\right]$ and $[\mathrm{PdLCl}(\mathrm{DMSO})]$ complexes in Tris- $\mathrm{HCl} 5 \mathrm{mM}, \mathrm{NaCl} 100$ $\mathrm{mM}, \mathrm{pH} 7.4$ at $25{ }^{\circ} \mathrm{C}$. (A) $\left[\mathrm{Pd}(\mathrm{L})_{2}\right]$ from $4.92 \times 10^{-6}$ to $4.87 \times 10^{-5} \mathrm{M}$; (B) [PdLCl(DMSO)] from $4.92 \times 10^{-6}$ to $5.84 \times 10^{-5}$ M ; (C) Lambert-Beer plots at 371 nm of $\left[\operatorname{Pd}(\mathrm{L})_{2}\right]\left(\varepsilon=1.11 \times 10^{4} \mathrm{M}^{-1} \mathrm{~cm}^{-1}\right.$, blue dot) and [PdLCl(DMSO)] $(\varepsilon=$ $1.05 \times 10^{4} \mathrm{M}^{-1} \mathrm{~cm}^{-1}$, orange square); (D) Absorbance ratio plots of $\left[\operatorname{Pd}(\mathrm{L})_{2}\right]\left(\mathrm{A}_{299} / \mathrm{A}_{371}\right.$, blue dot) and [PdLCI(DMSO)] ( $\mathrm{A}_{300} / \mathrm{A}_{371}$, orange square).


Figure S6. (A), (C) Stability of $\left[\operatorname{Pd}(\mathrm{L})_{2}\right]$ as a function of the temperature (from 25 to $95{ }^{\circ} \mathrm{C}$ ) in (A) PBS (phosphate $50 \mathrm{mM}, \mathrm{NaCl} 150 \mathrm{mM}, \mathrm{pH} 7.2$ ), and (C) Tris- $\mathrm{HCl} 5 \mathrm{mM} / \mathrm{NaCl} 100 \mathrm{mM}$ ( pH 7.4 ) buffers; (B), (D) Stability of [PdLCl(DMSO)] with temperature in (B) PBS and (D) Tris- $\mathrm{HCl} / \mathrm{NaCl}$ buffers (arrows: temperature increase from 25 to $95{ }^{\circ} \mathrm{C}$ C. . $\mathrm{C}_{\text {complex }}=3.57 \times 10^{-5} \mathrm{M}$.

Table S2. $\mathrm{IC}_{50}$ and selective index values of $\left[\mathrm{Pd}(\mathrm{L})_{2}\right],[\mathrm{PdLCl}(\mathrm{DMSO})]$ and cisplatin after 72 h of incubation with HL-60, Caco-2 and PC-3 cells.

|  | $\mathrm{IC}_{50}(\mu \mathrm{M})$ |  |  | Selective Index |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Complex | HL-60 | Caco-2 | PC-3 | Caco-2 | PC-3 |
| $\left[\mathrm{Pd}(\mathrm{L})_{2}\right]$ | $>10(* \mathrm{OOR})$ | $2.10 \pm 0.03$ | $1.25 \pm 0.13$ | 0.16 | 0.09 |
| $[\mathrm{PdLCl}(\mathrm{DMSO})]$ | $>10(* \mathrm{OOR})$ | $2.40 \pm 0.06$ | $1.22 \pm 0.09$ | 0.22 | 0.11 |
| Cisplatin | $0.62 \pm 0.05$ | $0.16 \pm 0.00$ | $<0.08(* \mathrm{OOR})$ | 0.26 | 0.13 |

[^0]Table S3. Effect of $\left[\mathrm{Pd}(\mathrm{L})_{2}\right]$ and $[\mathrm{PdLCl}(\mathrm{DMSO})]$ complexes in the cell cycle distribution of Caco-2 and PC-3 cell line after 72 h of treatment. Controls are depicted as negative cells ( C -: exposed to no treatment) and cisplatin, as reference compound. Cell cycle checkpoint activation was evaluated by flow cytometry (FACs Melody). Data shown as mean $\pm$ S.D of two assays in triplicates.

| Cell line | Phase | C- | $\left[\mathrm{Pd}(\mathrm{L})_{2}\right]$ | [PdLCI(DMSO)] | Cisplatin |
| :---: | :---: | :---: | :---: | :---: | :---: |
| PC-3 | G0/G1 | $11.1 \pm 2.0$ | $2.2 \pm 0.3$ | $13.1 \pm 4.2$ | $0.0 \pm 0.0$ |
|  | S | $56.3 \pm 3.0$ | $94.5 \pm 4.0$ | $99.3 \pm 1.0$ | $100.0 \pm 0.0$ |
|  | G2/M | $37.6 \pm 5.5$ | $0.5 \pm 0.1$ | $0.1 \pm 0.0$ | $0.18 \pm 0.1$ |
| Caco-2 | G0/G1 | $0.9 \pm 0.1$ | $5.4 \pm 0.9$ | $6.6 \pm 0.5$ | $6.5 \pm 1.3$ |
|  | S | $99.0 \pm 4.7$ | $89.0 \pm 2.3$ | $81.2 \pm 6.2$ | $77.0 \pm 3.5$ |
|  | G2/M | $2.8 \pm 0.3$ | $3.1 \pm 0.1$ | $0.1 \pm 0.0$ | $0.1 \pm 0.0$ |



Figure S7. Subcellular distribution of $\left[\mathrm{Pd}(\mathrm{L})_{2}\right],[\mathrm{PdLCl}(\mathrm{DMSO})]$ and their respective precursors in A$) \mathrm{Caco-}-2$ and B$)$ PC-3 cells after 72 h of incubation with $5 \mu \mathrm{M}$ of each complex. Data are expressed as the metal content ( $\mu \mathrm{g} \cdot \mathrm{L}^{-1}$ ) in the nucleus ( N ) or cytoplasm (C).


Figure S8. Spectrophotometric titrations of (A) $\left[\mathrm{Pd}(\mathrm{L})_{2}\right] / \mathrm{DNA}\left(\mathrm{C}_{\text {complex }}=1.06 \times 10^{-5} \mathrm{M}, \mathrm{C}_{\mathrm{DNA}}\right.$ from 0 (solid) to $1.67 \times 10^{-5} \mathrm{M}$ (dashed)); (B) [PdLCI(DMSO)]/DNA ( $\mathrm{C}_{\text {complex }}=1.06 \times 10^{-5} \mathrm{M}, \mathrm{C}_{\mathrm{DNA}}$ from 0 (solid) to $1.69 \times 10^{-5} \mathrm{M}$ (dashed)); (C) $\left[\mathrm{Pd}(\mathrm{L})_{2}\right] /$ poly $(\mathrm{rA})$ •poly $(\mathrm{rU})\left(\mathrm{C}_{\text {complex }}=1.06 \times 10^{-5} \mathrm{M}, \mathrm{C}_{\text {poly(ra) }}\right.$ poly(ru) from 0 (solid) to $8.10 \times 10^{-6} \mathrm{M}$ (dashed)); (D) [PdLCl(DMSO)]/poly(rA)•poly(rU) ( $\mathrm{C}_{\text {complex }}=1.06 \times 10^{-5} \mathrm{M}, \mathrm{C}_{\text {poly(ra) }}$ poly(ru) from 0 (solid) to $8.10 \times 10^{-6}$ M (dashed)); ( E ) $\left[\mathrm{Pd}(\mathrm{L})_{2}\right] /$ poly $(\mathrm{rA})\left(\mathrm{C}_{\text {complex }}=1.06 \times 10^{-5} \mathrm{M}, \mathrm{C}_{\text {poly(ra) }}\right.$ from 0 (solid) to $3.32 \times 10^{-5} \mathrm{M}$ (dashed)); (F) [PdLCl(DMSO)]/poly(rA) ( $\mathrm{C}_{\text {complex }}=1.06 \times 10^{-5} \mathrm{M}, \mathrm{C}_{\text {poly(rA) }}$ from 0 (solid) to $2.70 \times 10^{-5} \mathrm{M}$ (dashed)); (G) $\left[\mathrm{Pd}(\mathrm{L})_{2}\right] /$ poly $(\mathrm{rU}) \cdot$ poly $(\mathrm{rA})^{*}$ poly(rU) $\left(\mathrm{C}_{\text {complex }}=1.06 \times 10^{-5} \mathrm{M}, \mathrm{C}_{\text {poly(ru) }} \text { poly(ra) }\right)^{*}$ poly(ru) from 0 (solid) to $5.41 \times 10^{-6} \mathrm{M}$ (dashed)); and (H) [PdLCl(DMSO)]/poly(rU).poly(rA)*poly(rU) ( $\mathrm{C}_{\text {complex }}=1.06 \times 10^{-5} \mathrm{M}, \mathrm{C}_{\text {poly(ru).poly(ra) }}$ *poly(ru) from 0 (solid) to $5.41 \times 10^{-6} \mathrm{M}$ (dashed)); Tris- $\mathrm{HCl} 5 \mathrm{mM}, \mathrm{NaCl} 100 \mathrm{mM}, \mathrm{pH} 7.4,25{ }^{\circ} \mathrm{C}$.

Table S4. DNA/BSA binding constants $\left(K_{b}\right)$ values for different $\operatorname{Pd}(I I)$-thiosemicarbazone complexes. DNA is always natural DNA from calf thymus. The Log $K$ ranges are related to the fact that the reference considers a series of derivatives of the same $\mathrm{Pd}(\mathrm{II})$ complex.

| DNA BUFFER | pH | $\mathrm{T}\left({ }^{\circ} \mathrm{C}\right)$ | DNA conc* | $\begin{gathered} \text { DNA } \\ \log K_{\mathrm{b}} \end{gathered}$ | $\begin{gathered} \text { BSA } \\ \log K_{b} \end{gathered}$ | REF/DOI |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Tris- $\mathrm{HCl}(5 \mathrm{mM}$ ) $\mathrm{NaCl}(100 \mathrm{Mm})$ | 7.4 | 25 | bp | 6.0-6.1 | 6.5-7.2 | This work |
| Tris-HCl (5 mM), $\mathrm{NaCl}(50 \mathrm{mM})$ | 7.4 | 37 | bp | 4.6-6.2 |  | 10.1016/j.jinorgbio.2019.110875 |
| Tris- $\mathrm{HCl}(5 \mathrm{mM}$ ) $\mathrm{NaCl}(50 \mathrm{mM})$ | 7.2 | RT | P | 4.4-5.2 |  | 10.1016/j.ica.2021.120440 |
| Tris- HCl ( 5 mM ) $\mathrm{NaCl}(50 \mathrm{Mm})$ | 7.2 | RT | P | 5.0-5.7 | 4.5-6.8 | 10.1021/acs.inorgchem.0c02373 |
| Tris-HCl ( 5 mM ) $\mathrm{NaCl}(50 \mathrm{Mm})$ | 7.2 | RT | P | 4.5-5.7 | 4.1-4.5 | 10.1016/j.molstruc.2020.127703 |
| Tris-HCl ( 5 mM ) $\mathrm{NaCl}(50 \mathrm{Mm})$ | 7.2 | RT | P | 4.8-6.3 |  | 10.1002/aoc. 3813 |
| Tris-HCl ( 5 mM ) $\mathrm{NaCl}(50 \mathrm{mM})$ | 7.2 | RT | P | 4.8 |  | 10.1016/j.jinorgbio.2014.04.017 |
| Tris-HCl ( 5 mM ) $\mathrm{NaCl}(50 \mathrm{Mm})$ | 7.2 | rRT | P | 3.8-4.4 | 5.8-6.0 | 10.1021/ic302258k |

*DNA conc = way DNA concentration is expressed for $K_{\mathrm{b}}$ calculations, bp meaning in base pairs units while P is phosphates units. The difference between $b p$ and $P$ is supposed to produce no more than 0.3 increase in $\log K_{b}$ estimation in $P$.


Figure S9. Binding isotherms of fluorescence exchange reaction of (A) EtBr-saturated DNA with $\left[\mathrm{Pd}(\mathrm{L})_{2}\right]\left(\mathrm{C}_{\text {EtBr }}=\right.$ $9.16 \times 10^{-5} \mathrm{M}, C_{D N A}=2.40 \times 10^{-4} \mathrm{M}, C_{\text {complex }}$ from 0 to $3.94 \times 10^{-4} \mathrm{M}$ ) and [PdLCI(DMSO)] (C $\mathrm{C}_{\text {EtBr }}=9.16 \times 10^{-5} \mathrm{M}, \mathrm{C}_{\mathrm{DNA}}=$ $2.40 \times 10^{-4} \mathrm{M}, \mathrm{C}_{\text {complex }}$ from 0 to $5.68 \times 10^{-4} \mathrm{M}$ ), Tris- $\mathrm{HCl} 5 \mathrm{mM}, \mathrm{NaCl} 100 \mathrm{mM}, \mathrm{pH} 7.4,25{ }^{\circ} \mathrm{C}, \lambda_{\text {exc }}=510 \mathrm{~nm}, \lambda_{\mathrm{em}}=$ 595 nm ; (B) Et-Br-saturated RNA (poly(rA) poly(rU)) with $\left[\mathrm{Pd}(\mathrm{L})_{2}\right]\left(\mathrm{C}_{\mathrm{EtBr}}=7.83 \times 10^{-5} \mathrm{M}, \mathrm{C}_{\mathrm{RNA}}=2.42 \times 10^{-5} \mathrm{M}\right.$, $\mathrm{C}_{\text {complex }}$ from 0 to $3.33 \times 10^{-4} \mathrm{M}$ ) and [PdLCI(DMSO)] ( $\mathrm{C}_{\text {EtBr }}=7.83 \times 10^{-5} \mathrm{M}, \mathrm{C}_{\text {RNA }}=2.42 \times 10^{-5} \mathrm{M}, \mathrm{C}_{\text {complex }}$ from 0 to $3.32 \times 10^{-4} \mathrm{M}$ ) Tris-HCl $5 \mathrm{mM}, \mathrm{NaCl} 100 \mathrm{mM}, \mathrm{pH} 7.4,25{ }^{\circ} \mathrm{C}, \lambda_{\text {exc }}=450 \mathrm{~nm}, \lambda_{\text {em }}=585 \mathrm{~nm}$.

Table S5. Crystal data and structure refinement results for compound [PdLCI(DMSO)].

| Chemical formula | $\mathrm{C}_{18} \mathrm{H}_{22} \mathrm{ClN}_{5} \mathrm{O}_{3} \mathrm{PdS}_{2}$ |
| :---: | :---: |
| Formula weight ( $\mathrm{g} \mathrm{mol}^{-1}$ ) | 562.37 |
| Temperature (K) | 296(2) |
| Crystal system | monoclinic |
| Wavelength ( $\AA$ ) | 0.71073 |
| Space group | $P 121 / \mathrm{c} 1$ |
| Crystal size (mm) | $0.040 \times 0.043 \times 0.135$ |
| $a(\AA)$ | 11.2627(6) |
| $b(\AA)$ | 26.5445(12) |
| $c(\AA)$ | 15.8940(7) |
| $\alpha\left({ }^{\circ}\right.$ ) | 90 |
| $\beta\left({ }^{\circ}\right.$ ) | 109.7256(14) |
| $\gamma\left({ }^{\circ}\right.$ ) | 90 |
| Volume ( $\AA^{\mathbf{3}}$ ) | 4472.9(4) |
| Z | 8 |
| Density, calculated (g cm ${ }^{-3}$ ) | 1.670 |
| Absorption coefficient ( $\mathrm{mm}^{-1}$ ) | 1.166 |
| F(000) | 2272 |
| $\theta$ range for data collection ( ${ }^{\circ}$ ) | 1.53-25.35 |
| Reflections collected | 70909 |
| Independent reflections | 8190 [R(int) $=0.1394$ ] |
| Coverage of independent collections (\%) | 100.0 |
| Data/restrains/parameters | 8190 / 0 / 549 |
| Goodness of fit on $\mathrm{F}^{\mathbf{2}}$ | 1.035 |
| Final R indices [ $1>2 \sigma(I)]$ / all data | $\begin{aligned} & \mathrm{R} 1=0.0499 / 0.1260 \\ & \mathrm{wR} 2=0.1084 / 0.1643 \end{aligned}$ |
| Largest diff. peak and hole, (e $\AA^{-3}$ ) | 0.705 and -0.848 |


[^0]:    *OOR: Out of Range)

